AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04634890 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.
Study NCT03113916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Lifestyle Intervention
Description: A culturally tailored behavioral intervention.
Study NCT02752204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AZD 2014
Description: AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
Study NCT02752204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
Study NCT04192370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 600mg
Description: All subjects will receive 600mg of oral cannabidiol for 3 days in an open-label fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL, and the drug will be procured by the Brigham and Women's Hospital (BWH) Investigational Drug Services (IDS) pharmacy. The first dose will be administered at the BWH Center for Clinical Investigation, while doses 2 and 3 will be self-administrated at home. The CBD will be repacked in pre-drawn syringes for the subjects to self-administer at home.
Study NCT04187677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory Training
Description: The sensory training group includes sensory-oriented interventions and exercises unlike the other classical hand therapy group.
Study NCT04187677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical hand therapy
Description: classical hand therapy
Study NCT02891161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: 1500 mg Q4 weekly
Study NCT02891161 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
Study NCT04220827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IP
Study NCT02361749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
Study NCT04266769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LightForce Orthodontic System
Description: The LightForce Orthodontic System is a a digital treatment planning platform and patient-specific 3D printed polycrystalline alumina brackets for the treatment of malocclusion
Study NCT02423772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)
Study NCT02887573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Free-residue nutrients
Description: This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
Study NCT02887573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low fiber diet
Description: Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
Study NCT02887573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy
Description: In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
Study NCT02887573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG
Description: 2L PEG are laxatives for experiment group.
Study NCT02887573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4L PEG
Description: 4L PEG are laxatives in the control group.
Study NCT02887573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
Study NCT02887573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: 5mg mosapride citrate are used to promote gastric motivity.
Study NCT04679584 — intervention group
Intervention type: OTHER
Intervention: Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings
Description: Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care
Study NCT01371201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: sunitinib 37.5 mg per day
Study NCT01371201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 37.5 mg per day
Study NCT03683355 — intervention group
Intervention type: RADIATION
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
Study NCT01872715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oracea
Study NCT00112723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00501241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATI-7505
Description: Tablet,placebo, BID
Study NCT00501241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: ATI-7505 20 mg BID for 4 weeks
Study NCT00501241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: tablet, 40 mg, BID, $ weeks
Study NCT00501241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: 80 mg ATI-7505, BID for 4 weeks
Study NCT00501241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: 120 mg ATI-7505, BID, for 4 weeks
Study NCT03034733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
Study NCT03034733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride, (24)NaCl 0,9%
Description: intravenous placebo
Study NCT04763317 — intervention group
Intervention type: GENETIC
Intervention: Prostate cancer risk gene panel
Description: A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
Study NCT04222244 — intervention group
Intervention type: OTHER
Intervention: No intervention will be administered. We are only performing tests and measures.
Description: No intervention will be administered. We are only performing tests and measures.
Study NCT02307123 — intervention group
Intervention type: PROCEDURE
Intervention: Intubation
Description: HEMS physician prehospital intubation
Study NCT00800124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cemented Landos prosthesis vs. uncemented Landos prosthesis
Description: randomization between the cemented and non-cemented prosthesis.
Study NCT02223793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information on high risk factor levels and lifestyle advice
Description: This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
Study NCT02223793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No information on high risk factor levels but lifestyle advice
Description: In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
Study NCT02223793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No information on high risk factor levels, nor lifestyle advice
Description: In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
Study NCT04364880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBS
Description: Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
Study NCT04364880 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham-TBS coil produced a similar sound without a magnetic pulse.
Study NCT04516213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral Formula With (PHGG)
Description: Pediatric subjects will be fed a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)
Study NCT03201094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: Neuromuscular electrical stimulation twice daily during study period.
Study NCT03179748 — intervention group
Intervention type: DRUG
Intervention: turoctocog alfa
Description: Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
Study NCT03827005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: NOW Foods, Bloomingdale, IL
Study NCT03827005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-arginine
Description: NOW Foods, Bloomingdale, IL
Study NCT03827005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: InHealth Specialty Pharmacy, Fargo, ND
Study NCT01244984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/GW642444 Inhalation Powder
Description: Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
Study NCT03201094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Protein Supplementation
Description: High protein supplementation with whey protein shakes taken three times a day during study period.
Study NCT01244984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate Inhalation Powder
Description: Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
Study NCT01262495 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cryopreservation
Description: cryopreservation of testicular tissue
Study NCT02017834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection
Description: neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
Study NCT02017834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical resection
Description: neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
Study NCT01348581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marigen Wound Dressing
Description: The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
Study NCT03307590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Caudal block by dexmedetomidine and bupivavaine
Study NCT03307590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Caudal block by bupivavaine alone
Study NCT02989025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17 OHPC
Description: The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
Study NCT01961180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipralex
Description: the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
Study NCT03827005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: InHealth Specialty Pharmacy, Fargo, ND
Study NCT00440622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
Study NCT00440622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
Study NCT00440622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Description: Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
Study NCT02795676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRX-102 (pegunigalsidase alfa)
Description: PRX-102 1 mg/kg every 2 weeks
Study NCT02795676 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: agalsidase beta
Description: agalsidase beta 1 mg/kg every 2 weeks
Study NCT00943813 — intervention group
Intervention type: BEHAVIORAL
Intervention: video-recording and completing a survey
Description: Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, I disagree completely  to 5, I agree completely .
Study NCT03061903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.~Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device.
Study NCT03061903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel
Description: Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.~AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device.
Study NCT05080140 — intervention group
Intervention type: DRUG
Intervention: Ezetimibe 10mg
Description: Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites
Study NCT01961180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03956108 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI+targeted biopsies+Stockholm3-test
Description: MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.
Study NCT03956108 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PSA + systematic biopsies
Description: Systematic biopsies and PSA test
Study NCT00480025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1572932A Antigen-Specific Cancer Immunotherapeutic
Description: Intramuscular administration, 13 doses
Study NCT00480025 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Intramuscular administration, 13 doses
Study NCT00373360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil sodium
Description: rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
Study NCT04391608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switching to Tenofovir Alafenamide
Description: Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
Study NCT04577183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD1 System
Description: The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
Study NCT02741479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airplane Test
Description: The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time
Study NCT02741479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Airplane Test
Description: The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time
Study NCT04477798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PCT-DIA/MS
Description: PCT-DIA/MS will be validated to classify FNA biopsy specimens
Study NCT00350181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in the respective arm.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
Study NCT00350181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
Study NCT00350181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 15 mg/kg, IV
Study NCT00350181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: 60 mg/kg, IV
Study NCT01115062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera Patch
Description: Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
Study NCT00350181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
Study NCT00350181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTBI
Description: 1320 cGy delivered in 11 120 cGy fractions over 4 day
Study NCT00350181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BU
Description: BU 1 mg/kg every 6hr x 4 doses, IV
Study NCT02763020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit extracts high in polyphenols
Study NCT01115062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMX 4 Cream
Description: LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
Study NCT02763020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00724061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon α-2b
Description: PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.
Study NCT00724061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psoralens with ultraviolet light A
Description: Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.
Study NCT00724061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrowband-ultraviolet light B
Description: The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.